α-Synuclein (61-95) (human)
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) [1][2].
Product Specifications
CAS Number
154040-19-4
UNSPSC
12352209
Target
α-synuclein
Type
Peptides
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/α-synuclein-61-95-human.html
Solubility
10 mM in DMSO
Smiles
[C@H](CC1=CC=CC=C1)(C(N[C@@H](C(C)C)C(O)=O)=O)NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCC(O)=O)N)=O)CCC(N)=O)=O)[C@H](C)C)=O)[C@@H](C)O)=O)CC(N)=O)=O)[C@H](C)C)=O)=O)=O)C)=O)[C@H](C)C)=O)C(C)C)=O)[C@@H](C)O)=O)=O)[C@H](C)C)=O)[C@@H](C)O)=O)C)=O)[C@H](C)C)=O)C)=O)CCC(N)=O)=O)CCCCN)=O)[C@@H](C)O)=O)C(C)C)=O)CCC(O)=O)=O)=O)C)=O)=O)CO)=O)[C@H](CC)C)=O)C)=O)C)=O)C)=O)[C@@H](C)O)=O)=O
Molecular Formula
C141H235N39O49
Molecular Weight
3260.61
References & Citations
[1]Tabner BJ, et al. Formation of hydrogen peroxide and hydroxyl radicals from A (beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med. 2002 Jun 1;32 (11) :1076-83.|[2]Emadi S, et al. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry. 2004 Mar 16;43 (10) :2871-8.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
α-synuclein
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb1055070 100 µL
Angiopoietin-1 Rabbit Polyclonal Antibody (Cy5.5)
Sign In for Pricing
View Details 